Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Diabetic Foot Ulcers-Pipeline Review, H1 2015

Diabetic Foot Ulcers-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Diabetic Foot Ulcers-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diabetic Foot Ulcers-Pipeline Review, H1 2015', provides an overview of the Diabetic Foot Ulcers's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diabetic Foot Ulcers and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diabetic Foot Ulcers pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diabetic Foot Ulcers Overview 8

Therapeutics Development 9

Pipeline Products for Diabetic Foot Ulcers-Overview 9

Pipeline Products for Diabetic Foot Ulcers-Comparative Analysis 10

Diabetic Foot Ulcers-Therapeutics under Development by Companies 11

Diabetic Foot Ulcers-Therapeutics under Investigation by Universities/Institutes 15

Diabetic Foot Ulcers-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Diabetic Foot Ulcers-Products under Development by Companies 20

Diabetic Foot Ulcers-Products under Investigation by Universities/Institutes 23

Diabetic Foot Ulcers-Companies Involved in Therapeutics Development 24

Adocia 24

Aprogen, Inc. 25

CardioVascular BioTherapeutics, Inc. 26

Celgene Corporation 27

CoDa Therapeutics, Inc. 28

CytoTools AG 29

Derma Sciences, Inc. 30

Dipexium Pharmaceuticals LLC 31

EyeGene, Inc. 32

FirstString Research, Inc. 33

GlaxoSmithKline plc 34

Innovaxis 35

Izun Pharmaceuticals Corporation 36

Karyopharm Therapeutics, Inc. 37

Kasiak Research Pvt. Ltd. 38

Lumosa Therapeutics Co., Ltd. 39

Lytix Biopharma AS 40

MacroCure Ltd. 41

MediaPharma s.r.l. 42

NovaLead Pharma Pvt. Ltd. 43

Oneness Biotech Co., Ltd. 44

Plurogen Therapeutics, Inc. 45

Reliance Life Sciences Pvt. Ltd. 46

Royer Biomedical, Inc. 47

Sanofi 48

Stratatech Corporation 49

TechnoPhage SA 50

Tissue Med Biosciences 51

USV Limited 52

Vyome Biosciences Private Limited 53

Diabetic Foot Ulcers-Therapeutics Assessment 54

Assessment by Monotherapy Products 54

Assessment by Target 55

Assessment by Mechanism of Action 57

Assessment by Route of Administration 59

Assessment by Molecule Type 61

Drug Profiles 63

aclerastide-Drug Profile 63

ALLO-ASC-Drug Profile 65

AP-102-Drug Profile 66

APO-2-Drug Profile 67

becaplermin-Drug Profile 68

Biochaperone PDGF-BB-Drug Profile 69

Cathelicidin-Drug Profile 71

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers-Drug Profile 73

CL-05-Drug Profile 74

CODA-001-Drug Profile 76

CSTC-1-Drug Profile 78

CureXcell-Drug Profile 79

CVBT-141B-Drug Profile 80

Cyndacel-M-Drug Profile 82

daprodustat-Drug Profile 83

Drug for Diabetic Foot Ulcer-Drug Profile 85

EG-Decorin-Drug Profile 86

epidermal growth factor biosimilar-Drug Profile 87

esmolol hydrochloride-Drug Profile 88

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers-Drug Profile 89

gentamicin sulfate-Drug Profile 90

Granexin-Drug Profile 91

Heberprot-P-Drug Profile 92

IMSP-001-Drug Profile 93

IZN-6D4-Drug Profile 94

LTX-109-Drug Profile 95

MPHE-001A-Drug Profile 97

MT-003-Drug Profile 98

Mul-1867-Drug Profile 99

Nu-2-Drug Profile 100

Nu-3-Drug Profile 101

ON-101-Drug Profile 102

PDA-002-Drug Profile 103

pexiganan acetate-Drug Profile 104

PluroGel N-Drug Profile 106

Refaheal-Drug Profile 107

ReliDerm-DT-Drug Profile 108

selinexor-Drug Profile 109

STD-06-Drug Profile 114

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology-Drug Profile 115

TMBP-3-Drug Profile 117

TP-102-Drug Profile 118

Vasculotide-Drug Profile 119

Vivefoot-Drug Profile 120

Diabetic Foot Ulcers-Recent Pipeline Updates 121

Diabetic Foot Ulcers-Dormant Projects 138

Diabetic Foot Ulcers-Discontinued Products 141

Diabetic Foot Ulcers-Product Development Milestones 142

Featured News & Press Releases 142

Appendix 148

Methodology 148

Coverage 148

Secondary Research 148

Primary Research 148

Expert Panel Validation 148

Contact Us 148

Disclaimer 149

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H1 2015 12

Number of Products under Development for Diabetic Foot Ulcers-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Comparative Analysis by Unknown Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Diabetic Foot Ulcers-Pipeline by Adocia, H1 2015 27

Diabetic Foot Ulcers-Pipeline by Aprogen, Inc., H1 2015 28

Diabetic Foot Ulcers-Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015 29

Diabetic Foot Ulcers-Pipeline by Celgene Corporation, H1 2015 30

Diabetic Foot Ulcers-Pipeline by CoDa Therapeutics, Inc., H1 2015 31

Diabetic Foot Ulcers-Pipeline by CytoTools AG, H1 2015 32

Diabetic Foot Ulcers-Pipeline by Derma Sciences, Inc., H1 2015 33

Diabetic Foot Ulcers-Pipeline by Dipexium Pharmaceuticals LLC, H1 2015 34

Diabetic Foot Ulcers-Pipeline by EyeGene, Inc., H1 2015 35

Diabetic Foot Ulcers-Pipeline by FirstString Research, Inc., H1 2015 36

Diabetic Foot Ulcers-Pipeline by GlaxoSmithKline plc, H1 2015 37

Diabetic Foot Ulcers-Pipeline by Innovaxis, H1 2015 38

Diabetic Foot Ulcers-Pipeline by Izun Pharmaceuticals Corporation, H1 2015 39

Diabetic Foot Ulcers-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 40

Diabetic Foot Ulcers-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 41

Diabetic Foot Ulcers-Pipeline by Lumosa Therapeutics Co., Ltd., H1 2015 42

Diabetic Foot Ulcers-Pipeline by Lytix Biopharma AS, H1 2015 43

Diabetic Foot Ulcers-Pipeline by MacroCure Ltd., H1 2015 44

Diabetic Foot Ulcers-Pipeline by MediaPharma s.r.l., H1 2015 45

Diabetic Foot Ulcers-Pipeline by NovaLead Pharma Pvt. Ltd., H1 2015 46

Diabetic Foot Ulcers-Pipeline by Oneness Biotech Co., Ltd., H1 2015 47

Diabetic Foot Ulcers-Pipeline by Plurogen Therapeutics, Inc., H1 2015 48

Diabetic Foot Ulcers-Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2015 49

Diabetic Foot Ulcers-Pipeline by Royer Biomedical, Inc., H1 2015 50

Diabetic Foot Ulcers-Pipeline by Sanofi, H1 2015 51

Diabetic Foot Ulcers-Pipeline by Stratatech Corporation, H1 2015 52

Diabetic Foot Ulcers-Pipeline by TechnoPhage SA, H1 2015 53

Diabetic Foot Ulcers-Pipeline by Tissue Med Biosciences, H1 2015 54

Diabetic Foot Ulcers-Pipeline by USV Limited, H1 2015 55

Diabetic Foot Ulcers-Pipeline by Vyome Biosciences Private Limited, H1 2015 56

Assessment by Monotherapy Products, H1 2015 57

Number of Products by Stage and Target, H1 2015 59

Number of Products by Stage and Mechanism of Action, H1 2015 61

Number of Products by Stage and Route of Administration, H1 2015 63

Number of Products by Stage and Molecule Type, H1 2015 65

Diabetic Foot Ulcers Therapeutics-Recent Pipeline Updates, H1 2015 124

Diabetic Foot Ulcers-Dormant Projects, H1 2015 141

Diabetic Foot Ulcers-Dormant Projects (Contd..1), H1 2015 142

Diabetic Foot Ulcers-Dormant Projects (Contd..2), H1 2015 143

Diabetic Foot Ulcers-Discontinued Products, H1 2015 144

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H1 2015 12

Number of Products under Development for Diabetic Foot Ulcers-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 57

Number of Products by Stage and Top 10 Targets, H1 2015 58

Number of Products by Top 10 Mechanism of Actions, H1 2015 60

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 60

Number of Products by Top 10 Routes of Administration, H1 2015 62

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 63

Number of Products by Top 10 Molecule Types, H1 2015 64

Number of Products by Stage and Top 10 Molecule Types, H1 2015 64

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adocia

Aprogen, Inc.

CardioVascular BioTherapeutics, Inc.

Celgene Corporation

CoDa Therapeutics, Inc.

CytoTools AG

Derma Sciences, Inc.

Dipexium Pharmaceuticals LLC

EyeGene, Inc.

FirstString Research, Inc.

GlaxoSmithKline plc

Innovaxis

Izun Pharmaceuticals Corporation

Karyopharm Therapeutics, Inc.

Kasiak Research Pvt. Ltd.

Lumosa Therapeutics Co., Ltd.

Lytix Biopharma AS

MacroCure Ltd.

MediaPharma s.r.l.

NovaLead Pharma Pvt. Ltd.

Oneness Biotech Co., Ltd.

Plurogen Therapeutics, Inc.

Reliance Life Sciences Pvt. Ltd.

Royer Biomedical, Inc.

Sanofi

Stratatech Corporation

TechnoPhage SA

Tissue Med Biosciences

USV Limited

Vyome Biosciences Private Limited

Diabetic Foot Ulcers Therapeutic Products under Development, Key Players in Diabetic Foot Ulcers Therapeutics, Diabetic Foot Ulcers Pipeline Overview, Diabetic Foot Ulcers Pipeline, Diabetic Foot Ulcers Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com